The effects of prognostic factors on transplant and mortality of patients with end-stage liver disease using Markov multistate model

被引:0
|
作者
Madreseh, Elham [1 ,2 ]
Mahmoudi, Mahmood [1 ]
Toosi, Mohssen Nassiri [3 ]
Abolghasemi, Jamileh [4 ]
Zeraati, Hojjat [1 ]
机构
[1] Univ Tehran Med Sci, Sch Publ Hlth, Dept Epidemiol & Biostat, Tehran, Iran
[2] Univ Tehran Med Sci, Rheumatol Res Ctr, Tehran, Iran
[3] Univ Tehran Med Sci, Liver Transplantat Res Ctr, Imam Khomeini Hosp Complex, Tehran, Iran
[4] Iran Univ Med Sci, Sch Publ Hlth, Dept Biostat, Tehran, Iran
来源
关键词
Cirrhosis; life expectancy; model for end-stage liver disease; survival; LONG-TERM SURVIVAL; WAITING-LIST; LIFE EXPECTANCY; MELD; RECIPIENTS; CIRRHOSIS; SCORE; BENEFIT; HEALTH; STATES;
D O I
10.4103/jrms.jrms_1091_21
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Decompensated cirrhosis patients have a high risk of death which can be considerably reduced with liver transplantation (LT). This study aimed to simultaneously investigate the effect of some patients' characteristics on mortality among those with/without LT and also LT incident.Materials and Methods: In this historical cohort study, the information from 780 eligible patients aged 18 years or older was analyzed by the Markov multistate model; they had been listed between 2008 and 2014, needed a single organ for initial orthotopic LT, and followed at least for up to 5 years.Results: With a median survival time of 6 (5-8) years, there were 275 (35%) deaths. From 255 (33%) patients who had LT, 55 (21%) subsequently died. Factors associated with a higher risk of mortality and LT occurrence were included: higher model for end-stage liver disease (MELD) score (hazard ratio [HR] = 1.16, confidence interval [CI]: 1.09-1.24 and HR = 1.22, CI: 1.41-1.30) and ascites complication (HR = 2.34, CI: 1.74-3.16 and HR = 11.43, CI: 8.64-15.12). Older age (HR = 1.03, CI: 1.01-1.06), higher creatinine (HR = 6.87, CI: 1.45-32.56), and autoimmune disease versus hepatitis (HR = 2.53, CI: 1.12-5.73) were associated with increased risk of mortality after LT.Conclusion: The MELD and ascites are influential factors on waiting list mortality and occurrence of LT. Total life expectancy is not influenced by higher MELD.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Model for End-Stage Liver Disease Underestimates Morbidity and Mortality in Patients with Ascites Undergoing Colectomy
    Matthew M. Fleming
    Fangfang Liu
    Yawei Zhang
    Kevin Y. Pei
    World Journal of Surgery, 2018, 42 : 3390 - 3397
  • [42] Model for End-Stage Liver Disease score predicts mortality in critically ill cirrhotic patients
    Boone, M. Dustin
    Celi, Leo A.
    Ho, Ben G.
    Pencina, Michael
    Curry, Michael P.
    Lior, Yotam
    Talmor, Daniel
    Novack, Victor
    JOURNAL OF CRITICAL CARE, 2014, 29 (05) : 881.e7 - 881.e13
  • [43] Model for End-Stage liver Disease (MELD) for predicting mortality in patients with acute variceal bleeding
    Chalasani, N
    Kahi, C
    Francois, F
    Pinto, A
    Marathe, A
    Bini, EJ
    Pandya, P
    Sitaraman, S
    Shen, JZ
    HEPATOLOGY, 2002, 35 (05) : 1282 - 1284
  • [44] Model for end-stage liver disease (MELD) predicts nontransplant surgical mortality in patients with cirrhosis
    Northup, PG
    Wanamaker, RC
    Lee, YD
    Adams, RB
    Berg, CL
    ANNALS OF SURGERY, 2005, 242 (02) : 244 - 251
  • [45] Acute rise in delta model for end-stage liver disease as a prognostic risk factor for post-transplant mortality: an analysis of a national registry
    Cholankeril, G.
    Gadiparthi, C.
    Khan, M. A.
    Satapathy, S.
    Hu, M.
    Nair, S.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S442 - S442
  • [46] Impact of the Model for End-Stage Liver Disease Score on Mortality After Liver Transplantation
    Cabeza de Vaca, V. G.
    Bellido, C. B.
    Martinez, J. N. A.
    Artacho, G. S.
    Gomez, L. M. M.
    Diaz-Canedo, J. S.
    Ruiz, F. J. P.
    Bravo, M. A. G.
    TRANSPLANTATION PROCEEDINGS, 2012, 44 (07) : 2069 - 2070
  • [47] Could tenofovir modify the model end-stage liver disease (MELD) score in patients with end-stage liver disease eligible for liver transplantation?
    Bruno, Raffaele
    Sacchi, Paolo
    Filice, Gaetano
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 45 (01) : 123 - 123
  • [48] Comparison of transient elastography and Model for End-Stage Liver Disease-sodium to Model for End-Stage Liver Disease-sodium alone to predict mortality and liver transplantation
    Trivedi, Hirsh D.
    Danford, Christopher J.
    Iriana, Sentia
    Ochoa-Allemant, Pedro
    Rourke, Meredith
    Yang, Kuen-Cheh
    Curry, Michael P.
    Lai, Michelle
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 : E753 - E757
  • [49] Model for end-stage liver disease limbo, model for end-stage liver disease purgatory, and the dilemma of treating hepatitis C in patients awaiting liver transplantation
    Carrion, Andres F.
    Khaderi, Saira A.
    Sussman, Norman L.
    LIVER TRANSPLANTATION, 2016, 22 (03) : 279 - 280
  • [50] Comparison of transient elastography and Model for End-Stage Liver Disease-sodium to Model for End-Stage Liver Disease-sodium alone to predict mortality and liver transplantation
    Trivedi, Hirsh D.
    Danford, Christopher J.
    Iriana, Sentia
    Ochoa-Allemant, Pedro
    Rourke, Meredith
    Yang, Kuen-Cheh
    Curry, Michael P.
    Lai, Michelle
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (1S) : E753 - E757